Protective effects of SGLT2 inhibitors’ action in various states and conditions, including cancer, metabolic diseases, and others, by affecting ncRNAs expression were demonstrated in cultured cells, animal models, and patient studies for a number of SGLT2 inhibitors [8]. This evidence concerns the gene SLC5A2 and metabolic disease.